X4 Pharmaceuticals (NASDAQ:XFOR) Releases Earnings Results, Beats Expectations By $0.05 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) issued its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05, Zacks reports. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%.

X4 Pharmaceuticals Trading Up 0.5%

Shares of XFOR stock traded up $0.02 on Thursday, hitting $4.17. 447,777 shares of the stock traded hands, compared to its average volume of 545,007. The firm’s 50-day moving average price is $4.02 and its two-hundred day moving average price is $3.94. The stock has a market capitalization of $393.31 million, a PE ratio of -0.92 and a beta of 0.37. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares of the company’s stock, valued at $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC lifted its stake in X4 Pharmaceuticals by 227.0% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after purchasing an additional 5,530,866 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in X4 Pharmaceuticals during the fourth quarter worth approximately $14,891,000. Braidwell LP acquired a new stake in X4 Pharmaceuticals during the fourth quarter worth approximately $13,476,000. Nantahala Capital Management LLC purchased a new stake in shares of X4 Pharmaceuticals during the 3rd quarter worth approximately $7,621,000. Finally, Siren L.L.C. purchased a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth approximately $6,000,000. Hedge funds and other institutional investors own 72.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, X4 Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $9.70.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.